

Clinical Policy: Benzphetamine

Reference Number: CP.CPA.326

Effective Date: 06.01.18

Last Review Date: 05.26

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Benzphetamine is a sympathomimetic amine with pharmacologic activity similar to the amphetamines.

FDA Approved Indication(s)

Benzphetamine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m² or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that benzphetamine is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Weight Management** (must meet all):

1. Member meets one of the following (a, b, or c):
 - a. BMI \geq 30 kg/m²;
 - b. BMI \geq 27 kg/m² with at least one indicator of increased cardiovascular risk (e.g., coronary artery/heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference) or other obesity-related medical condition (e.g., sleep apnea);
 - c. If age < 18 years: BMI \geq 95th percentile standardized for age and sex (*see Appendix D*);
2. Age \geq 17 years;
3. Documentation supports member's participation in a weight loss program that involves a reduced calorie diet, increased physical activity, and behavioral modification that meets both of the following (a and b):
 - a. Been actively enrolled in a weight loss program for at least 6 months;
 - b. Will continue to be actively enrolled in a weight loss program adjunct to therapy;
4. Dose does not exceed 150 mg per day.

Approval duration: 12 weeks

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. Weight Management (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by weight loss (adults) or reduction of BMI (pediatrics) from baseline;
3. Documentation that member is actively enrolled in a weight loss program that involves a reduced calorie diet, increased physical activity, and behavioral modification adjunct to therapy;
4. Total treatment duration does not exceed 12 weeks;
5. If request is for a dose increase, new dose does not exceed 150 mg per day.

Approval duration: Up to 12 weeks total

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND

CLINICAL POLICY

Benzphetamine

criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

BMI: body mass index

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications & Boxed Warnings

- Contraindication(s): pregnancy, symptomatic cardiovascular disease, moderate to severe hypertension, history of drug abuse, hyperthyroidism, glaucoma, concomitant use or use within 14 days of MAO inhibitors, advanced arteriosclerosis, agitated states, concomitant use of CNS stimulants, and known hypersensitivity to sympathomimetic amines
- Boxed warning(s): none reported

Appendix D: General Information

- $BMI = 703 \times [\text{weight (lbs)/height (inches)}^2]$
- Examples of coronary artery/heart disease include coronary artery bypass graft, angina, history of myocardial infarction or stroke.
- If tolerance develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.
- The AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average).
 - A diet that is individually planned and takes into account the patient's overweight status in order to help create a deficit of 500 to 1,000 kcal/day should be an integral part of any weight loss program. A patient may choose a diet of 1,000 to 1,200 kcal/day for women and 1,200 to 1,500 kcal/day for men.
 - There is no standardized set of rules to optimize weight reduction with a given type of patient. A theoretical and qualitative analysis of cultural appropriateness in obesity treatment programs has been conducted, and it provides some guidance for incorporating patient characteristics and perspectives when designing and delivering weight loss programs.
 - Some examples follow: Adapt the setting and staffing to the patient population. The setting should: be physically accessible to the patient; have features likely to

CLINICAL POLICY
Benzphetamine

be familiar to the patient; be free of negative psychosocial connotations; be devoid of aspects that create a large social distance among patients or between patient and practitioner; and promote active patient participation and high patient self-esteem and self-efficacy.

- BMI cut-offs (95th percentile) for obesity by age and sex for pediatric patients aged ≥ 17 years:

| Age (in years) | 95 th Percentile BMI Value | |
|----------------|---------------------------------------|--------|
| | Male | Female |
| 17 | 28.2 | 29.6 |
| 17.5 | 28.6 | 30.0 |

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|-------------------|--------------------|--------------|
| Weight management | 25-50 mg PO QD-TID | 150 mg/day |

VI. Product Availability

Tablets: 25 mg, 50 mg

VII. References

1. Benzphetamine Prescribing Information. Sacramento, CA: Nivagen Pharmaceuticals; January 2016. Available at: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5f5b95b3-a18f-4289-b9a6-a3278ef5966d&type=pdf>. Accessed January 15, 2026.
2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014; 129(suppl 2): S102–S138.
3. NHLBI Obesity Education Initiative. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998 Sep. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf. Accessed January 15, 2026.
4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015; 100(2): 42-362.
5. Garvey WT, Mechanick JI, Bret EM et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract*. 2016 Jul;22 Suppl 3:1-203.12.
6. Grunvald E, Shah R, Hernaez R et al. AGA clinical practice guidelines on pharmacological interventions for adults with obesity. *Gastroenterology* 2022;163:1198-1225.
7. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity [published online ahead of print, 2023 Jan 9]. *Pediatrics*. 2023;e2022060640.

CLINICAL POLICY
Benzphetamine

8. Czepiel KS, Perez NP, Campoverde Reyes KJ et al. Pharmacotherapy for weight loss in children, adolescents, and young adults: an evaluation of current on- and off-label usage. *Pediatrics* March 2021; 147 (3_MeetingAbstract):180-181.
9. Data Table of BMI-for-Age Charts. CDC National Center for Health Statistics. Available at: <https://www.cdc.gov/growthcharts/cdc-charts.htm>. Accessed February 6, 2025.
10. American Diabetes Association Professional Practice Committee for Diabetes*; 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of care in diabetes–2026. *Diabetes Care* 1 January 2026; 49 (Supplement_1): S166–S182.
11. American Diabetes Association Professional Practice Committee for Obesity*; Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. *DOCM CARE* 11 February 2026; 1 (1): 5–36.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| 2Q 2022 annual review: no significant changes; removed references to Didrex due to discontinuation of product; references reviewed and updated. | 01.20.22 | 05.22 |
| Template changes applied to other diagnoses/indications and continued therapy section. | 09.23.22 | |
| 2Q 2023 annual review: for age 17 years, added obesity defined as BMI ≥ 95 th percentile standardized for age and sex per AAP; removed continued therapy criterion of BMI ≥ 25 kg/m ² ; added 25 mg strength tablet; references reviewed and updated. | 01.11.23 | 05.23 |
| 2Q 2024 annual review: for documentation of weight loss program, added members has been actively enrolled for at least 6 months to initial criteria and added a weight loss program that also involves behavioral modification as supported by ACC/AHA guidelines; references reviewed and updated. | 01.16.24 | 05.24 |
| 2Q 2025 annual review: no significant changes; references reviewed and updated. | 01.14.25 | 05.25 |
| 2Q 2026 annual review: for continued therapy, clarified positive response as evidenced by weight loss for adults and added reduction of BMI for pediatrics; references reviewed and updated. | 01.23.26 | 05.26 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical

CLINICAL POLICY

Benzphetamine

practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.